ReviewBioengineering (Basel, Switzerland)2025
Finite Element Modeling in Left Ventricular Cardiac Biomechanics: From Computational Tool to Clinical Practice.
Review in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cardiac mechanotransduction from development to disease.APL bioengineering · 2026Review
- Correction: Hoang, P.; Guccione, J. Finite Element Modeling in Left Ventricular Cardiac Biomechanics: From Computational Tool to Clinical Practice.Bioengineering (Basel, Switzerland) · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
Abstract
Finite element (FE) modeling has emerged as a powerful computational approach in cardiovascular biomechanics, enabling detailed simulations of myocardial stress, strain, and hemodynamics, which are challenging to measure with conventional imaging techniques. This narrative review explores the progression of cardiac FE modeling from research-focused applications to its increasing integration into clinical practice. Specific attention is given to the mechanical effects of myocardial infarction, the limitations of conventional LV volume-reduction surgeries, and novel therapeutic approaches like passive myocardial reinforcement via hydrogel injections. Furthermore, the review highlights the critical role of patient-specific FE simulations in optimizing LV assist device parameters and guiding targeted device placements. Cutting-edge developments in artificial intelligence-enhanced FE modeling, including surrogate models and precomputed simulation databases, are examined for their potential to facilitate real-time, personalized therapeutic decision-making. Collectively, these advancements position FE modeling as an essential tool in precision medicine for structural heart disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.